Stanley Druckenmiller Crinetics Pharmaceuticals, Inc. Transaction History
Duquesne Family Office LLC
- $4.39 Billion
- Q1 2024
A detailed history of Stanley Druckenmiller (Duquesne Family Office LLC) transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Duquesne Family Office LLC holds 309,000 shares of CRNX stock, worth $13.9 Million. This represents 0.33% of its overall portfolio holdings.
Number of Shares
309,000Holding current value
$13.9 Million% of portfolio
0.33%Shares
1 transactions
Others Institutions Holding CRNX
# of Institutions
220Shares Held
75.8MCall Options Held
631KPut Options Held
749K-
Black Rock Inc. New York, NY5.44MShares$244 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.23MShares$235 Million2.68% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.95MShares$222 Million0.59% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.16MShares$186 Million5.55% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.82MShares$172 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.41B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...